---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-027106"
form_type: "8-K"
ticker: "INMB"
cik: "0001711754"
company_name: "Inmune Bio, Inc."
filed_at: "2025-04-01T23:59:59+00:00"
generated_at: "2026-05-24T00:54:43.090970+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# INmune Bio presents MINDFuL Phase II baseline data at AD/PD 2025; topline results due June 2025

## Summary
- Poster details baseline demographics of 208 patients (44% MCI, 56% mild AD) enrolled in MINDFuL Phase II trial of XPro1595.
- 69.2% of patients are APOE ε4 carriers; 64.4% met inclusion criteria for more than one inflammation biomarker.
- Primary endpoint is change from baseline in Early and Mild Alzheimer's Cognitive Composite (EMACC) score; topline results expected June 2025.
- Patients randomized 2:1 to XPro 1.0 mg/kg or placebo once weekly for 23 weeks; screen failure rate was 72%.
- Baseline characteristics show similarity to Phase III trials; no efficacy data disclosed.

## SEC filing metadata
- accession: 0001213900-25-027106
- form_type: 8-K
- ticker: INMB
- cik: 0001711754
- company_name: Inmune Bio, Inc.
- filed_at: 2025-04-01T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711754/000121390025027106/0001213900-25-027106-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711754/000121390025027106/ea0236644-8k_inmune.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-027106
- JSON: https://secwatch.observer/filing/0001213900-25-027106.json
- Plain text: https://secwatch.observer/filing/0001213900-25-027106.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.